ESC 365 - Dual vs triple antithrombotic therapy: new evidence.

Open Access

Dual vs triple antithrombotic therapy: new evidence.

Session: RE-DUAL PCI and reversal: improving care decisions after coronary revascularisation

Topic: PCI: long-term outcome

Speaker: Professor C. Cannon (Boston, US)

Sponsored by Boehringer Ingelheim

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Christopher Paul Cannon

Brigham and Women's Hospital, Boston (United States of America)

38 presentations

0 follower

3 more presentations in this session

Antithrombotic strategies post-PCI: what do we know so far?

Speaker: Professor G. Nickenig (Bonn, DE)

Safety, efficacy, control: choosing the right oral anticoagulant for our patients.

Speaker: Professor T. Villines (Charlottesville, US)

Panel discussion Q&A - RE-DUAL PCI and reversal: improving care decisions after coronary revascularisation.

Speaker: Professor C. Cannon (Boston, US)

Access the full session

RE-DUAL PCI and reversal: improving care decisions after coronary revascularisation

Speakers: Professor C. Cannon, Professor G. Nickenig, Professor T. Villines, Professor C. Cannon

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources